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TaxaneObjectives: The effect of taxanes-based induction chemotherapy (IC) in locoregionally advanced nasopha-
ryngeal carcinoma (LA-NPC) was quite contradictory in two phase II randomized controlled trials with
small sample size. We aimed to investigate it in this large scale propensity-matched study.
Materials and methods: Totally, 779 LA-NPC patients who underwent intensity-modulated radiotherapy
(IMRT) plus concurrent chemotherapy with or without taxanes-based IC were included. Patients in both
treatment arms were matched using propensity score matching method at the ratio of 1:1. Failure-free
survival (FFS), overall survival (OS), distant metastasis-free survival (DMFS) and locoregional
relapse-free survival (LRFS) were assessed with Kaplan–Meier method, log-rank test and Cox regression
analysis.
Results: After matching, 534 patients were identiﬁed for analysis. In univariate analysis, both treatment
arms resulted in parallel survival (4-years FFS 78.0% vs 74.1%, P = 0.304; OS 87.5% vs 87.3%, P = 0.595;
DMFS 88.2% vs 84.4%, P = 0.154; and LRFS 91.2% vs 90.1%, P = 0.960). In multivariate analysis,
taxanes-based IC did not improve any survival (PP 0.139). And this association remained unchanged
in subgroup analysis by age, sex and histology, and among patients with stage III and T4N0M0. But among
patients with T4N1-2M0 and stage IVb, taxanes-based IC signiﬁcantly prolonged the 4-year DMFS by
11.2% (86.1% vs 74.9%, P = 0.034), and marginally improved FFS (P = 0.133) and OS (P = 0.215) in both
univariate and multivariate analysis.
Conclusions: In this large scale propensity-matched study, LA-NPC patients could not beneﬁt from
taxanes-based IC on the whole. But the risk of distant metastasis signiﬁcantly decreased by above 10%
for patients with T4N1-2M0 and stage IVb.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Nasopharyngeal carcinoma (NPC) is a distinct head and
neck carcinoma relatively rare in Europe and the United States
[1] but highly endemic in Southern China [2] and Hong Kong [3].
Radiotherapy is the cornerstone of initial treatment. In
recent years, several randomized controlled trials [4–9] and
meta-analysis [10] have conﬁrmed concurrent chemoradiotherapy
as the standard treatment for locoregionally advanced NPC
(LA-NPC). Unfortunately, concurrent chemoradiotherapy is not
adequate for certain high-risk patient groups, especially patients
with bulky and/or extensive nodal disease who have higher
potential for metastasis [11]. Adding induction chemotherapy
(IC) to concurrent chemoradiotherapy seems a logical strategy to
maximize the beneﬁt of chemotherapy in such patients.
L.-N. Zhang et al. / Oral Oncology 51 (2015) 950–956 951A randomized phase II trial [12] found that adding IC of doc-
etaxel and cisplatin to intensity-modulated radiotherapy (IMRT)
plus concurrent chemotherapy (CC) signiﬁcantly improved overall
survival (OS) of LA-NPC. However, only 65 patients were randomly
assigned to receive IMRT plus CC with (34 patients) or without (31
patients) IC. Thus the fact of inadequate participants possibly made
the results skewed. Secondly, patients treated with IMRT plus CC in
the control arm had remarkably lower 2-years OS rates than those
participated in another large phase III trial [13] (80% versus 92%),
despite the similar treatment and clinical stage. And there was a
sharp decrease of OS rates for patients in the control arm from
80.0% at 2-years to 67.7% at 3-years, which also indicated the inﬂu-
ence of small sample size on the survival outcome in this trial [12].
Inversely, a similar taxanes-based IC of paclitaxel, cisplatin and
epirubicin followed by concurrent chemoradiotherapy (72
LA-NPC patients) in another randomized phase II study [14] did
not signiﬁcantly improve response rates and/or survival compared
with that of concurrent chemoradiotherapy alone (69 patients). All
the patients in this trial underwent three-dimensional conformal
radiotherapy except 62 patients who were treated with
two-dimensional conventional radiotherapy (2DCRT) [14].
Therefore, it is still pending whether LA-NPC patients can beneﬁtTable 1
Baseline characteristics of nasopharyngeal carcinoma patients underwent intensity-m
chemotherapy.
Before propensity score matching
IC + IMRT + CC
(N = 280)
IMRT + CC (N = 499) P






Male 211 75.4 361 72.3
Female 69 24.6 138 27.7
Histologya 0
I + II 26 9.3 24 4.8
III 254 90.7 475 95.2
VCA-IgAb 0
<80 44 15.7 89 17.8
80–320 74 26.4 168 33.7
P320 162 57.9 242 48.5
EA-IgAb 0
<10 63 22.5 147 29.5
10–40 95 33.9 154 30.9
P40 122 43.6 198 39.7
T-stage <0
T1 5 1.8 16 3.2
T2 14 5.0 32 6.4
T3 136 48.6 305 61.1
T4 125 44.6 146 29.3
N-stage <0
N0 33 11.8 125 25.1
N1 168 60.0 257 51.5
N2 61 21.8 96 19.2
N3 18 6.4 21 4.2
Clinical stage <0
III 144 51.4 335 67.1
IVa 118 42.1 143 28.7
IVb 18 6.4 21 4.2
Abbreviations: IC = induction chemotherapy, IMRT = intensity-modulated radiotherapy,
EA = early antigen, IgA = immunoglobulin A.
a Based on the criteria of WHO histological type (1991): I – Keratinising squamous-c
non-keratinising carcinoma.
b In accordance with the criteria adopted in previous studies.
c Fisher’s exact test.from the additional taxanes-based IC when receiving the recom-
mended treatment of IMRT plus CC.
To address this question, we included 779 LA-NPC patients who
received the treatment of IMRT plus CC with or without
taxanes-based IC, and analyzed the effect of taxanes-based IC using
propensity score matching method, which is often conceptualized
as mimicking randomized trials [15]. This large scale
propensity-matched study shall provide valuable information of




This study was approved by the Institutional Review Board at
our center, and individual informed consent was waived given
the anonymous analysis of routine data. Between March 2003
and November 2012, 779 biopsy-proven, non-metastatic and
treatment-naïve NPC patients who were at the age of 20 or above
were entered into this study. All patients had complete pretreat-
ment evaluation including patient history, physical examination,odulated radiotherapy plus concurrent chemotherapy with or without induction
After propensity score matching
IC + IMRT + CC
(N = 267)
IMRT + CC (N = 267) P






202 75.7 195 73.0
65 24.3 72 27.0
.014 0.478
19 7.1 15 5.6
248 92.9 252 94.4
.038 0.266
44 16.5 47 17.6
73 27.3 88 33.0
150 56.2 132 49.4
.110 0.489
63 23.6 75 28.1
93 34.8 86 32.2
111 41.6 106 39.7
.001 0.742c
5 1.9 2 0.7
14 5.2 14 5.2
136 50.9 142 53.2
112 41.9 109 40.8
.001 0.956
33 12.4 36 13.5
165 61.8 161 60.3
55 20.6 54 20.2
14 5.2 16 6.0
.001 0.915
144 53.9 145 54.3
109 40.8 106 39.7
14 5.2 16 6.0
CC = concurrent chemotherapy, SD = standard deviation, VCA = viral capsid antigen,
ell carcinoma, II – Differentiated non-keratinising carcinoma, III – Undifferentiated
952 L.-N. Zhang et al. / Oral Oncology 51 (2015) 950–956hematology and biochemistry proﬁles, ﬁberoptic nasopharyn-
goscopy with biopsy, magnetic resonance imaging (MRI) of the
nasopharynx and neck, chest radiography, abdominal sonography
and Technetium-99m-methylene diphosphonate (Tc-99-MDP)
whole-body bone scan. Patients were restaged with T1-2N2-3M0
or T3-4N0-3M0 in accordance with the seventh edition of the
International Union against Cancer/American Joint Committee on
Cancer (UICC/AJCC) staging system for NPC.
Treatment
All patients were treated by deﬁnitive IMRT plus CC with or
without IC. The cumulative radiation doses were 68 Gy or greater
to the primary tumor, 60–66 Gy to the involved cervical lymph
nodes and 50 Gy or greater to potential sites of local inﬁltration
and bilateral cervical lymphatics in 30–33 fractions. Further details
of the radiation technique have been described previously [16]. All
patients were delivered with the CC regimen of cisplatin weekly or
every three weeks during radiotherapy. IC consisted of docetaxel/
paclitaxel plus cisplatin, or docetaxel/paclitaxel plus cisplatin plus
ﬂuorouracil given every three weeks for two to three cycles before
radiotherapy.
Follow-up
Patients were examined every 3–6 months during the ﬁrst
3 years, and every 6–12 months thereafter until death. During this
period, patients were assessed by history and physical examination
and a series of conventional examination equipment at eachFig. 1. Kaplan–Meier survival curves for the taxanes-based IC and IMRT plus CC arm a
CC = concurrent chemotherapy, IC = induction chemotherapy, IMRT = intensity-modulatefollow-up visit, to detect the possible relapse or distant metastasis.
Local relapses were conﬁrmed by biopsy, MRI scan, or both.
Regional relapses were diagnosed by clinical examination and an
MRI scan of the neck and, in doubtful cases, by ﬁne needle aspira-
tion of the lymph nodes. Distant metastases were diagnosed by
clinical symptoms, physical examinations, and imaging methods
including chest radiography, bones scan, MRI, and abdominal
sonography. Patients without recent examination tests in the med-
ical records were followed up by telephone call.
Statistical analysis
Patients treated with IC and IMRT plus CC were selected to
match those treated with IMRT plus CC using propensity score
matching method. This method creates similar case (IC and IMRT
plus CC) and control (IMRT plus CC) arms, and reduces possible
biases to a minimum in a retrospective analysis [17]. Propensity
scores were computed by logistic regression for each patient based
on the presumed covariates, including age, sex, histology, titers of
immunoglobulin A against viral capsid antigen (VCA-IgA) and
immunoglobulin A against early antigen (EA-IgA) of Epstein–Barr
virus, T-stage, N-stage and clinical stage. Patients were then
matched without replacement at the ratio of 1:1 on those scores,
rather than the individual covariates. Covariates balance between
the two sets were examined by t test (continuous variable), v2 test
or Fisher’s exact test (categorical variable) as appropriate.
Failure free survival (FFS), overall survival (OS), distant
metastasis-free survival (DMFS) and locoregional relapse-freend the IMRT plus CC alone arm in the propensity-matched cohort of 534 patients.
d radiotherapy.
L.-N. Zhang et al. / Oral Oncology 51 (2015) 950–956 953survival (LRFS) were estimated with the Kaplan–Meier method
[18]. Crude and adjusted hazard ratios with 95% conﬁdence
intervals (with IMRT plus CC as reference) were calculated using
Cox regression analysis [19]. FFS was calculated from the date of
treatment to the date of ﬁrst treatment failure (distant metastasis
or locoregional relapse) or death from any cause. OS, DMFS and
LRFS were deﬁned as the time from treatment to death from any
cause, to the ﬁrst distant metastasis and to the ﬁrst locoregional
relapse, respectively.
All statistical analyses were performed using IBM SPSS Statistics
version 22.0. Two-sided P values < 0.05 were considered to be
signiﬁcant.Table 2
Summary of important prognostic factors in multivariate analysis in the propensity-
matched cohort.a
Hazard ratio (95% CI) P
Failure free survival
IC + IMRT + CC versus IMRT + CC 0.82 (0.59–1.16) 0.261
Age (continuous) 1.02 (1.00–1.04) 0.044
Sex 0.83 (0.55–1.26) 0.379
T-stage 1.74 (1.31–2.31) <0.001
N-stage 1.75 (1.38–2.22) <0.001
Overall survival
IC + IMRT + CC versus IMRT + CC 0.88 (0.57–1.37) 0.569
Age (continuous) 1.04 (1.02–1.07) 0.001
Sex 0.65 (0.36–1.18) 0.153
T-stage 1.94 (1.33–2.81) 0.001
N-stage 1.97 (1.46–2.65) <0.001
Distant metastasis-free survival
IC + IMRT + CC versus IMRT + CC 0.71 (0.45–1.12) 0.139
Age (continuous) 1.02 (0.99–1.04) 0.151
Sex 0.85 (0.49–1.49) 0.570
T-stage 1.45 (1.02–2.07) 0.039
N-stage 2.10 (1.56–2.84) <0.001
Locoregional relapse-free survival
IC + IMRT + CC versus IMRT + CC 0.96 (0.55–1.67) 0.889
Age (continuous) 1.01 (0.98–1.04) 0.636
Sex 0.82 (0.42–1.60) 0.556
T-stage 2.00 (1.20–3.34) 0.008
N-stage 1.09 (0.70–1.68) 0.712
Abbreviations: CI = conﬁdence interval, IC = induction chemotherapy,
IMRT = intensity-modulated radiotherapy, CC = concurrent chemotherapy.
a Adjusted for T-stage, N-stage with Enter method and age (continuous), sex,
histology, VCA-IgA (<80/80-320/P320), EA-IgA (<10/10-40/P40) with Backward LR
method.
Table 3
Subgroup analysis by prognostic factors in multivariate analysis in the propensity-matche
N Failure free survival Overall survival
Hazard ratio (95% CI) P Hazard ratio (95% CI
Age
<45 ys 139vs137 0.81 (0.50–1.30) 0.380 1.01 (0.52–1.96)
P45 ys 128vs130 0.84 (0.52–1.35) 0.463 0.75 (0.42–1.37)
Sex
Male 202vs195 0.80 (0.55–1.18) 0.259 0.93 (0.58–1.50)
Female 65vs72 0.93 (0.45–1.93) 0.844 0.76 (0.25–2.36)
Histology
II 19vs15 0.04 (0.00–1.95) 0.106 0.03 (0.00–10.2)
III 248vs252 0.86 (0.61–1.22) 0.402 0.89 (0.57–1.41)
Stage
III+T4N0 163vs160 1.04 (0.64–1.70) 0.867 1.30 (0.66–2.59)
T4N1-2+IVb 104vs107 0.69 (0.43–1.10) 0.114 0.68 (0.38–1.22)
Abbreviations: CI = conﬁdence interval.
a Adjusted for T-stage, N-stage with Enter method and age (continuous), sex, histologyResults
Patients
Among the 779 patients, 280 (35.9%) and 499 (64.1%) patients
were treated with IMRT plus CC with and without taxanes-based
IC, respectively. The baseline characteristics of patients were
showed in Table 1. When patients were stratiﬁed according to ini-
tial treatment (IC and IMRT plus CC versus IMRT plus CC), statisti-
cally signiﬁcant differences were recorded with respect to age
(P = 0.001), histology (P = 0.014), titer of VCA-IgA (P = 0.038),
T-stage (P < 0.001), N-stage (P < 0.001) and clinical stage
(P < 0.001). Following propensity score matching, 267 (50%)
patients treated with IC and IMRT plus CC and 267 (50%) patients
treated with IMRT plus CC remained in the analysis. The included
patients after matching in the two arms had highly balanced char-
acteristics, including mean age, sex, histology, titers of VCA-IgA
and EA-IgA, T-stage, N-stage and clinical stage. All subsequent
analyses were based on the propensity-matched cohort.
Survival outcomes
The median follow-up time was 50.30 months (10.30–
117.10 months) for the IC and IMRT plus CC arm, and 55.27 months
(6.27–134.70 months) for the IMRT plus CC arm, respectively. In
univariate analysis, IC and IMRT plus CC resulted in parallel sur-
vival to IMRT plus CC alone (FFS rates at 4-years 78.0% vs 74.1%,
P = 0.304; OS rates at 4-years 87.5% vs 87.3%, P = 0.595; DMFS rates
at 4 years 88.2% vs 84.4%, P = 0.154; and LRFS rates at 4 years 91.2%
vs 90.1%, P = 0.960; Fig. 1A–D). In multivariate analysis, the addi-
tion of taxanes-based IC to IMRT plus CC did not signiﬁcantly lower
the risk of treatment failure, death, distant metastasis or locore-
gional relapse, in comparison with IMRT plus CC alone (Table 2).
Subgroup analysis
In subgroup analysis by age (<45/P45 years), sex and histology,
IC and IMRT plus CC showed no signiﬁcant survival differences
from IMRT plus CC alone (Table 3).
When focusing on patients with stage III and T4N0M0, no statis-
tically signiﬁcant differences were observed in 4-year FFS, OS,
DMFS and LRFS rates between patients treated with and without
IC (Fig. 2A–D, Table 3).
When focusing on patients with T4N1-2M0 and stage IVb, the





) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
0.979 0.60 (0.31–1.16) 0.131 1.21 (0.58–2.53) 0.616
0.351 0.89 (0.47–1.69) 0.727 0.68 (0.29–1.60) 0.381
0.765 0.77 (0.46–1.28) 0.314 0.89 (0.48–1.67) 0.724
0.639 0.59 (0.21–1.63) 0.309 1.33 (0.40–4.40) 0.638
0.239 0.07 (0.00–3.61) 0.183 – 0.968
0.629 0.75 (0.47–1.19) 0.220 1.08 (0.61–1.89) 0.799
0.451 1.08 (0.56–2.10) 0.818 0.93 (0.42–2.04) 0.854
0.196 0.50 (0.26–0.95) 0.034 1.01 (0.47–2.20) 0.972
, VCA-IgA (<80/80-320/P320), EA-IgA (<10/10-40/P40) with Backward LR method.
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(P = 0.034). Additionally, there was a marginal trend of decreasing
the risk of treatment failure (72.2% vs 62.2%, P = 0.133) and death
(83.6% vs 79.6%, P = 0.215). Yet the 4-year LRFS rates between the
two treatment arms were highly comparable (88.5% vs 87.6%,
P = 0.927) (Fig. 2E–H). Adjusting for the covariates, the effect of
taxanes-based IC on lowering the risk of distant metastasis
remained signiﬁcant (P = 0.034). Unfortunately, IC still could not
signiﬁcantly prolong FFS, OS or LRFS in this subgroup of high risk
patients (Table 3).Fig. 2. Kaplan–Meier survival curves for the taxanes-based IC and IMRT plus CC arm an
subgroup of patients with stage III and T4N0M0; E–H, the subgroup of patients with T4N
IMRT = intensity-modulated radiotherapy.Discussion
Investigators previously sought to improve the survival of
LA-NPC by adding IC of bleomycin plus epirubicin plus cisplatin
[20], epirubicin plus cisplatin [21], cisplatin plus ﬂuorouracil [22]
or cisplatin plus ﬂuorouracil plus bleomycin [23] to 2DCRT. But
none of the IC regimes succeeded. This may be attributed to the
absence of the most efﬁcacious regimen. When the signiﬁcant
superiorities in OS by adding docetaxel or paclitaxel to cisplatin
and ﬂuorouracil (PF) versus PF alone as induction regimen wered the IMRT plus CC alone arm in the subgroup stratiﬁed by tumor stage. A–D, the
1-2M0 and stage IVb. CC = concurrent chemotherapy, IC = induction chemotherapy,
Fig. 2 (continued)
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expected to result in encouraging beneﬁt in LA-NPC.
Unfortunately, the conﬂicting ﬁndings of the trial by Hui et al.
[12] and the trial by Fountzilas et al. [14] made the beneﬁt unde-
termined. The small sample size in these two trials greatly
increased the uncertainty of the conclusions.
The present study enrolled a total of 779 patients, and identiﬁed
267 patients with taxanes-based IC and IMRT plus CC and 267
patients with IMRT plus CC alone for analysis using propensity
score matching method. Based on the adequate participants and
the design of mimicking randomized control trial [15], we found
no survival beneﬁt for LA-NPC patients by adding taxanes-based
IC to IMRT plus CC in comparison with IMRT plus CC alone on
the whole. But the risk of distant metastasis was signiﬁcantly
reduced by above 10% in the subgroup of patients with
T4N1-2M0 and stage IVb.
Actually, four phase III randomized controlled trails demon-
strated that patients with locally advanced head and neck cancers
did not beneﬁt from IC of docetaxel, cisplatin and ﬂuorouracil fol-
lowed by concurrent chemoradiotherapy compared with concur-
rent chemoradiotherapy alone [28–31]. This gives a hint that
taxanes-based IC may also fail to produce encouraging effects on
LA-NPC. In the 2DCRT alone era, a nonsigniﬁcant trend in favor of
the former usual IC regimens was found in LA-NPC patients [20–
23]. Considering the signiﬁcant superiority of IMRT versus 2DCRT
in local control and OS [32], and the conﬁrmed improvement in
survival by CC [4–10], it is more difﬁcult to further raise the sur-
vival of patients who receive IMRT plus CC by adding
taxanes-based IC. The decreased differences demands the larger
sample size in theory. Thus the failure of taxanes-based IC in this
present study is possibly associated with the overestimated sur-
vival differences and the underestimated sample size, since only
534 NPC patients were included for analysis whereas the trials of
breast cancer [33], lung cancer [34] and colon cancer [35] com-
monly enrolled thousands of patients. As NPC is extremely rare
compared with breast cancer, lung cancer and colon cancer, inves-
tigators are usually obliged to reduce the sample size on one hand,
and on the other to include all LA-NPC patients instead of the
selected high risk ones. For example, patients with T4N1-2M0
and stage IVb achieved signiﬁcantly lower risk of developing dis-
tant metastasis, and marginal improvement of FFS and OS with
taxanes-based IC. Thus this regimen is highly potential to signiﬁ-
cantly prolong FFS and even OS if sufﬁcient patients with
T4N1-2M0 and stage IVb are enrolled in the future studies.
Owing to the heterogeneity of tumor, larger differences can indeed
be sought in a better selected population using speciﬁc prognostic
factors such as EBV DNA [36] or microRNA [37].The major strength of this study lies in the investigation of
taxanes-based IC effect in LA-NPC with the largest sample size
using propensity score matching and multivariate analysis. This
greatly addressed the limitations of divergent confounders and
selection bias associated with the retrospective assessment of
observational data [17]. Although the presented data was derived
from a single institution in endemic area with expertise in diagnos-
ing and treating this disease, it did provide valuable information on
the effect of taxanes-based IC before the ﬁnal report of any phase 3
randomized controlled trial (RCT). Moreover, the results gave sug-
gestions and warnings of avoiding underestimation of the sample
size and better targeting the high risk patients in the future RCTs.
The major limitation is the missing data on treatment toxicity
caused by the retrospective design and the long intervals between
the ﬁrst and the last included cases. But the fact of additional tox-
icity from IC and of possibly similar toxicity from IMRT plus CC in
the two arms was beyond dispute. Since data on DNA copy number
of the Epstein–Barr virus was missing in most of cases, VCA-IgA
and EA-IgA were taken as the surrogate. Additionally, the
Karnofsky index was inaccurate or missing in a considerable pro-
portion of patients. But actually, the Karnofsky index was not sig-
niﬁcantly prognostic in FFS, OS, DMFS or LRFS, as observed in the
previous RCT [13]. So the avoidance of matching the Karnofsky
index is less likely to cause skewed results, in comparison with
the small sample size of matched patients if the Karnofsky index
was forced to be considered.
Overall, this large scale propensity score matched study indi-
cated no survival beneﬁt from the addition of taxanes-based IC
before IMRT plus CC for LA-NPC. But the risk of distant metastasis
signiﬁcantly decreased by above 10% as the result of IC in the
subgroup of patients with T4N1-2M0 and stage IVb. Further conﬁr-
mation by prospectively randomized controlled trial is warranted.
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